Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial
Hong Zhao, Chi Zhang, Qi Zhu, Xianxiang Chen, Guilin Chen, Wenjin Sun, Zuohan Xiao, Wei-Jun Du, Jing Yao, Guojun Li, Yanhua Ji, Niuniu Li, Yujin Jiang, Ying Wang, Qingjin Zeng, Wei Li, Beilei Gong, Xianyou Chang, Feng Zhu, Xiufeng Jiang, Jiawen Li, Zhao Wu, Yingxia Liu, Peng Peng, Guiqiang Wang
Topics & Concepts
FavipiravirOpen labelMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Randomized controlled trialCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakMulticenter trialMulticenter studyPharmacologyVirologyInternal medicineOutbreakDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 detection and testingLong-Term Effects of COVID-19